Siamycin I
Description
Siamycin I (BMY-29304) is a 21-residue tricyclic peptide and a secondary metabolite of actinomycetes. Siamycin I is an HIV fusion inhibitor, with an ED50 of 0.05-5.7 ??M against acute HIV type 1 (HIV-1) and HIV-2 infection. Siamycin I inhibits gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling in a non-competitive manner through the FsrC-FsrA two-component regulatory system. Siamycin I inhibits the expression of fsrBDC and gelE-sprE transcripts. Siamycin I is a lasso peptide that interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I is an antibiotic with potential for research on enterococcal infections.
Product Details
| Product Name | Siamycin I |
| Biological activity | Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED50s of 0.05 to 5.7 ??M for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research. |
| Formula | C97H131N23O26S4 |
| CAS Number | 164802-68-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
